Influenza virus susceptibility and resistance to oseltamivir

Antiviral Therapy

Volumn 12, Issue 4 B, 2007, Pages 603-616

  Aoki, Fred Y ^a   Boivin, Guy ^b   Roberts, Noel ^c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; A 315675; OSELTAMIVIR; PERAMIVIR; SIALIDASE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CLINICAL TRIAL; HUMAN; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A H5N1; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS ISOLATION; VIRUS STRAIN;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HUMANS; INFANT; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H2N2 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; NEURAMINIDASE; OSELTAMIVIR;

EID: 34547730145     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Nicholson KG. Human influenza. In Textbook of Influenza, 1998; pp. 219-264. Edited by KG Nicholson, RG Webster & AJ Hay. Oxford: Blackwell Science.
2. Patriarca PA, Strikas RA. Influenza vaccine for healthy adults? N Engl J Med 1995; 333:933-934.
3. Centers for Disease Control and Prevention [homepage on the internet]. Department of Health and Human Services: Centers for Disease Control and Prevention; 2007 [cited March 2007]. Influenza (Flu). Available from http://www.cdc.gov/flu/
4. Dushoff J, Plotkin JB, Viboud C, Earn DJ, Simonsen L. Mortality due to influenza in the United States - an annualized regression approach using multiple-cause mortality data. Am J Epidemiol 2006; 163:181-187.
5. Department of Health and Human Services. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Weekly Rep 2002; 51 RR03:1-31.
6. rd Annual ASM Biodefense Research Meeting. 20-23 March 2003, Baltimore, USA. Poster 135.
7. Oxford JS, Lambkin R. Targeting influenza virus neuraminidase - a new strategy for antiviral therapy. Drug Discov Today 1998; 3:448-456.
8. Lin JT, Yu XZ, Cui DJ, et al. A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population. Curr Med Res Opin 2006; 22:75-82.
9. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355:1845-1850.
10. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283:1016-1024.
11. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20:127-133.
12. Hayden FG, Belshe R, Villanueva C, et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 2004; 189:440-449.
13. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001; 285:748-754.
14. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341:1336-1343.
15. Peters PH Jr, Gravenstein S, Norwood P, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 2001; 49:1025-1031.
16. Jackson HC, Roberts N, Wang ZM, Belshe R. Management of influenza: use of new antivirals and resistance in perspective. Clin Drug Invest 2000; 20:447-454.
17. Roberts NA. Treatment of influenza with neuraminidase inhibitors: virological implications. Philos Trans R Soc Lond B Biol Sci 2001; 356:1895-1897.
18. Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005; 55 Suppl 1:i5-i21.
19. Moscona A. Oseltamivir resistance - disabling our influenza defenses. N Engl J Med 2005; 353:2633-2636.
20. Hayden FG. Amantadine and rimantadine: clinical aspects. In Antiviral drug resistance, 1996; pp. 59-77. Edited by DD Richman. Chichester, UK: John Wiley & Sons.
21. McKimm-Breschkin JL, Sahasrabudhe A, Blick TJ, et al. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J Virol 1998; 72:2456-2462.
22. Russell RJ, Haire LF, Stevens DJ, et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006; 443:45-49.
23. Wang MZ, Tai CY, Mendel DB. Mechanism by which mutations at His274 alter sensitivity of influenza a virus N1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob Agents Chemother 2002; 46:3809-3816.
24. Yen HL, Herlocher LM, Hoffmann E, et al. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother 2005; 49:4075-4084.
25. Cheam AL, Barr IG, Hampson AW, Mosse J, Hurt AC. In vitro generation and characterisation of an influenza B variant with reduced sensitivity to neuraminidase inhibitors. Antivir Res 2004; 63:177-181.
26. Molla A, Kati W, Carrick R, et al. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675. J Virol 2002; 76:5380-5386.
27. Tai CY, Escarpe PA, Sidwell RW, et al. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 1998; 42:3234-3241.
28. Hayden FG. Amantadine and rimantadine resistance in influenza A viruses. Curr Opin Infect Dis 1994; 7:674-677.
29. Abed Y, Goyette N, Boivin G. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. Antivir Ther 2004; 9:577-581.
30. Jackson D, Barclay W, Zurcher T. Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations. J Antimicrob Chemother 2005; 55:162-169.
31. Yen HL, Hoffmann E, Taylor G, et al. Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J Virol 2006; 80:8787-8795.
32. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998; 178:1257-1262.
33. Tisdale M. Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Rev Med Virol 2000; 10:45-55.
34. Zambon M, Hayden FG. Position statement: global neuraminidase inhibitor susceptibility network. Antivir Res 2001; 49:147-156.
35. Hatakeyama S, Sakai-Tagawa Y, Kiso M, et al. Enhanced expression of an α2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor. J Clin Microbiol 2005; 43:4139-4146.
36. Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk HD. Overexpression of the α-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol 2003; 77:8418-8425.
37. Matrosovich M, Matrosovich T, Carr J. Further characterization of a laboratory cell line for detecting resistance to neuraminidase inhibitors. Options for the Control of Influenza V. 7-11 October 2003, Okinawa, Japan. Abstract W05-5.
38. Potier M, Mameli L, Belisle M, Dallaire L, Melancon SB. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-α-D- N-acetylneuraminate) substrate. Anal Biochem 1979; 94:287-296.
39. Members of Neuraminidase Inhibitor Susceptibility Network. Use of influenza antivirals during 2003-2004 and monitoring of neuraminidase inhibitor resistance. Wkly Epidemiol Rec; 80:156.
40. Parvin JD, Moscona A, Pan WT, Leider JM, Palese P. Measurement of the mutation rates of animal viruses: influenza A virus and poliovirus type 1. J Virol 1986; 59:377-383.
41. Rocha E, Cox NJ, Black RA, Harmon MW, Harrison CJ, Kendal AP. Antigenic and genetic variation in influenza A (H1N1) virus isolates recovered from a persistently infected immunodeficient child. J Virol 1991; 65:2340-2350.
42. Lin YP, Wharton SA, Martin J, Skehel JJ, Wiley DC, Steinhauer DA. Adaptation of egg-grown and transfectant influenza viruses for growth in mammalian cells: selection of hemagglutinin mutants with elevated pH of membrane fusion. Virology 1997; 233:402-410.
43. Schild GC, Oxford JS, de Jong JC, Webster RG. Evidence for host-cell selection of influenza virus antigenic variants. Nature 1983; 303:706-709.
44. McKimm-Breschkin J, Trivedi T, Hampson A, et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 2003; 47:2264-2272.
45. Ferraris O, Kessler N, Lina B. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antivir Res 2005; 68:43-48.
46. Boivin G, Goyette N. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. Antivir Res 2002; 54:143-147.
47. Hurt AC, Barr IG, Durrant CJ, Shaw RP, Sjogren HM, Hampson AW. Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia. Commun Dis Intell 2003; 27:542-547.
48. Monto AS, Kimm-Breschkin JL, Macken C, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006; 50:2395-2402.
49. Mungall BA, Xu X, Klimov A. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons. Virus Res 2004; 103:195-197.
50. Hurt AC, Iannello P, Jachno K, et al. Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient. Antimicrob Agents Chemother 2006; 50:1872-1874.
51. Hayden FG, Jennings L, Robson R, et al. Oral oseltamivir in human experimental influenza B infection. Antivir Ther 2000; 5:205-213.
52. Kawai N, Ikematsu H, Iwaki N, et al. Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season. Clin Infect Dis 2005; 40:1309-1316.
53. Kawai N, Ikematsu H, Iwaki N, et al. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. Clin Infect Dis 2006; 43:439-444.
54. Sugaya N, Mitamura K, Yamazaki M, et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 2007; 44:197-202.
55. Oo C, Hill G, Dorr A, Liu B, Boellner S, Ward P. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years. Eur J Clin Pharmacol 2003; 59:411-415.
56. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004; 364:759-765.
57. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 2001; 183:523-531.
58. Hatakeyama S, Sugaya N, Ito M, et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 2007; 297:1435-1442.
59. Ison MG, Mishin VP, Braciale TJ, Hayden FG, Gubareva LV. Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection. J Infect Dis 2006; 193:765-772.
60. Baz M, Abed Y, McDonald J, Boivin G. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis 2006; 43:1555-1561.
61. Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med 2003; 348:867-868.
62. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 2006; 193:760-764.
63. Carr J, Ives J, Kelly L, et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antivir Res 2002; 54:79-88.
64. Herlocher ML, Truscon R, Elias S, et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 2004; 190:1627-1630.
65. Herlocher ML, Carr J, Ives J, et al. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antivir Res 2002; 54:99-111.
66. Ives JA, Carr JA, Mendel DB, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antivir Res 2002; 55:307-317.
67. Gubareva LV, Robinson MJ, Bethell RC, Webster RG. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 1997; 71:3385-3390.
68. Abed Y, Baz M, Boivin G. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir Ther 2006; 11:971-976.
69. Kiso M, Balasingham S, Mann A. Reduced pathogenicity and transmissibility of an oseltamivir-resistant influenza virus A(H3N2) isolate (N2945). IX International Symposium on Respiratory Viral Infections. 3-6 March 2007, Hong Kong. Abstract II-2.
70. Sweet C, Hayden FG, Jakeman KJ, Grambas S, Hay AJ. Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets. J Infect Dis 1991; 164:969-972.
71. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989; 321:1696-1702.
72. Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, Barr IG. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antivir Res 2007; 73:228-231.
73. Rameix-Welti MA, Agou F, Buchy P, et al. Natural variation can significantly alter sensitivity to oseltamivir of Influenza A(H5N1) viruses. Antimicrob Agents Chemother 2006; 50:3809-3815.
74. de Jong MD, Tran TT, Truong HK, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353:2667-2672.
75. Le QM, Kiso M, Someya K, et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005; 437:1108
76. Reuters [homepage on the internet]. London: Reuters Group [updated 2007 February 13; cited 2007 February 13]. Egypt - latest bird flu deaths not Tamiflu resistant. Available from http://www.reuters.com/article/healthNews/ idUSL1362171020070213
77. Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 2005; 49:4515-4520.
78. Varghese JN, Smith PW, Sollis SL, et al. Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure 1998; 6:735-746.